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INTRODUCTION
As part of its mission, the FDA evaluates 
specific drugs and medical devices for safety 
and efficacy through meetings of special 
advisory committees such as the Dermatologic 
and Ophthalmic Drugs Advisory Committee 
(DODAC) and the Ophthalmic Devices Panel 
(ODP). Included in these meetings is an Open 
Public Hearing (OPH) portion, during which 
patients, physicians, drug representatives, 
advocacy groups, and other parties are allowed 
to present opinions on the drug or device. It 
has recently been called into question whether 
conflicts of interest may sway a speaker's 
argument toward approval of a drug or device.
OBJECTIVES
Our study investigated the financial conflicts of 
interest of open public hearing speakers at 
meetings of the Dermatologic and Ophthalmic 
Drug Advisory Committee and the Ophthalmic 
Devices Panel to determine whether a 
relationship exists between receipt of 
payments by public speakers and the nature of 
their recommendations regarding approval for 
the therapy.
METHODS
We identified DODAC and ODP meetings on the 
FDA website from February 2009 to December 
2019 and reviewed the published transcripts of 
these meetings.
We investigated DODAC and ODP meetings to 
evaluate the association between financial 
conflicts of interest and the likelihood that 
speakers would provide a positive testimony 
regarding a drug/device. Our results showed 
that speakers with a COI were significantly more 
likely to speak positively regarding the 
drug/device. Nearly one-half of the 86 Open 
Public Hearing speakers in our study had COIs 
involving the drug/device sponsor, with 
payments for travel and lodging being the most 
common. All of these speakers provided positive 
testimonies. The potential of COIs to heavily 
influence drug/device approval should be 
seriously considered by the DODAC and ODP. We 
recommend that the FDA require full disclosure 
of COI information from public speakers. Such a 
requirement would allow the committee to fully 
understand the context of the public speakers’ 
comments, allowing them to determine the 
comments’ validity.
Nature of Speaker Testimonies Based on COI
Table 1: Characteristics of Dermatologic and Ophthalmic Drug 
Advisory Committee (DODAC) and Ophthalmic Devices Panel 
(ODP) hearings
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Advisory 
Committee Drug/Device name Pharmaceutical company
# of 
speakers
# of speakers 
with COIs
ODP Implantable Miniature Telescope (IMT) VisionCare Technologies Inc. 7 4
DODAC Elyea (Aflibercept ophthalmic solution) Regeneron Pharmaceuticals, Inc. 2 1
DODAC Lucentis (Ranibizumab injection) Genentech Inc. 13 3
DODAC Jetrea (Ocriplasmin intravitreal injection) ThromboGenics, Inc. 5 2
ODP Argus II Retinal Prosthesis System Second Sight Medical Products, Inc. 9 2
ODP
Trulign Toric Accommodating Posterior Chamber 
Intraocular Lens Bausch + Lomb 2 1
ODP Visian Toric Implantable Collamer Lens STAAR Surgical Company 7 5
ODP Kamra Inlay AcuFocus, Inc. 4 4
DODAC Secukinumab Novartis 3 3
ODP
AcrySof IQ ReSTOR Multifocal Toric Posterior Chamber 
Intraocular Lens Alcon Inc. 8 5
DODAC and ODP Riboflavin ophthalmic solutions with UV-A irradiation Avedro Inc. 14 1
DODAC Deoxycholic acid injection Kythera Biopharmaceuticals 11 9
DODAC Brodalumab injection
Valeant Pharmaceuticals Luxembourg 
S.a.r.l. 1 1
• Data Points of Speakers:
• Affected by disease
• Treated with drug or device
• Reported COI
• Nature of Testimony:
• Positive
• Negative
• Neutral
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